Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069073 | 1.00 | L3MBTL1 (0.36) | L3MBTL1MMP13SLC7A5ITGA4ITGB7 | |
| SCHEMBL6068981 | 1.00 | L3MBTL1 (0.36) | L3MBTL1MMP13SLC7A5ITGA4ITGB7 | |
| SCHEMBL6068849 | 0.79 | CTSS (0.34) | L3MBTL1MMP13SLC7A5AAK1PPARG | |
| SCHEMBL7276228 | 0.74 | L3MBTL1 (0.47) | L3MBTL1 | |
| SCHEMBL7993296 | 0.74 | CYP2C19 (0.37) | L3MBTL1MMP13 | |
| SCHEMBL2580570 | 0.74 | L3MBTL1 (0.47) | L3MBTL1 | |
| SCHEMBL2945259 | 0.74 | SMN1; SMN2 (0.39) | L3MBTL1MMP13SLC7A5AAK1 | |
| SCHEMBL7993292 | 0.74 | CYP2C19 (0.37) | L3MBTL1MMP13 | |
| SCHEMBL1926702 | 0.72 | L3MBTL1 (0.41) | L3MBTL1 | |
| SCHEMBL1928928 | 0.72 | L3MBTL1 (0.40) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109234-B2 | Benzoxathiepine derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2006-09-19 | — | — | US | disclosed |
| EP-1370547-B1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PF MEDICAMENT (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | disclosed |
| EP-1370547-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002081464-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | CYP4A11, CYP3A4, CYP4F11 | L3MBTL1 3897/4885MMP13 1878/4885SLC7A5 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.